摘要To the Editor: In a single-center, prospective, randomized double-blind clinical study comparing dexmedetomidinemidazolam and sufentanil-midazolam sedation regimens for awake fiberoptic intubation (AFOI) in 50 patients with difficult airways due to limited mouth opening, Li et al.[1] show that both dexmedetomidine and sufentanil are effective as an adjuvant for AFOI under airway topical anesthesia combined with midazolam sedation, but respiratory depression is a potential risk in the sufentanil-midazolam regimen.Given that AFOI has been established as the gold standard for difficult airway management,[2]their findings have potentially clinical implications.In our view, however, there are several aspects of this study that need to be clarified and discussed.